Heart transplantation is a pivotal treatment of end-stage heart failure, and recent advancements have extended median posttransplant life expectancy. However, despite the progress in surgical techniques and medical treatment, heart transplant patients still face complications such as rejection, infections, and drug toxicity. CT is a reliable tool for detecting most of these complications, whereas MR imaging is particularly adept at identifying pericardial pathologies and signs of rejection. Awareness of these nuances by radiologists, cardiologists, and surgeons is desired to optimize care, reduce morbidities, and enhance survival.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.rcl.2023.12.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Establishing Cross-Specialty Expert Consensus on the Optimal Management of Hyperkalemia in Patients With Heart Failure and Chronic Kidney Disease.
Circ J
March 2025
Kawasaki Geriatric Medical Center, Kawasaki Medical School.
Background: Patients with both heart failure (HF) and chronic kidney disease (CKD) are often treated with renin-angiotensin-aldosterone system inhibitors (RAASi), but these drugs can cause hyperkalemia, which may lead to their reduction or discontinuation, resulting in the loss of their beneficial effects. Approaches to managing RAASi-induced hyperkalemia are discordant, so in this study we aimed to establish a cross-specialty consensus on the optimal approach to managing hyperkalemia in patients with HF and CKD.
Methods And Results: The study used a modified Delphi methodology.
The Final Rule in a Bind: What We Are Learning From Suboptimal Simultaneous Heart-Kidney Outcomes and Potential Solutions to the Problem.
Transplantation
November 2024
Division of Nephrology, University of Arizona, Tucson, AZ.
Background: The 2018 revision of the adult Heart Allocation Policy (aHAP) led to a notable increase in the rate of simultaneous heart-kidney transplants (SHKT) in the United States. However, this policy has faced criticism for its inability to enhance post-transplant survival rates or decrease mortality among SHKT recipients on the waitlist, although high-quality kidneys are used.
Methods: We analyzed data from the Organ Procurement and Transplantation Network, covering 1549 SHKT cases from 2015 to 2021.
Cirrhotic cardiomyopathy: comprehensive insights into pathophysiology, diagnosis, and management.
Heart Fail Rev
March 2025
Department of Internal Medicine, MedStar Union Memorial Hospital Baltimore, Baltimore, MD, USA.
Cirrhotic cardiomyopathy (CCM) is a cardiac dysfunction linked to chronic liver disease, primarily characterized by impaired cardiac response to stress, despite normal baseline function. It presents with both systolic and diastolic dysfunction, along with electrophysiological changes such as QT interval prolongation. CCM is driven by a combination of systemic inflammation, nitric oxide-induced vasodilation, and neurohormonal dysregulation, leading to myocardial impairment and abnormal vascular responses.
View Article and Find Full Text PDFStructure and function relationships of mucociliary clearance in human and rat airways.
Nat Commun
March 2025
Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Hastings Center for Pulmonary Research, University of Southern California, Los Angeles, CA, USA.
Mucociliary clearance is a vital defense mechanism of the human airways, protecting against harmful particles and infections. When this process fails, it contributes to respiratory diseases like chronic obstructive pulmonary disease (COPD) and asthma. While advances in single-cell transcriptomics have revealed the complexity of airway composition, much of what we know about how airway structure impacts clearance relies on animal studies.
View Article and Find Full Text PDFPractice and Outcome Trends of Peritoneal Dialysis in Chronic Kidney Disease Patients With Liver Cirrhosis and Chronic Heart Failure Complicated by Symptomatic Ascites-A Scoping Review.
Nephrology (Carlton)
March 2025
Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.
Background: The rising growth of patients with end-stage kidney disease (ESKD) associated with chronic liver disease (CLD) and refractory chronic heart failure (CHF) associated with advanced chronic kidney disease (CKD) complicated by ascites presents serious renal replacement therapy (RRT) challenges. Haemodialysis is often poorly tolerated owing to increased hemodynamic instability, bleeding, and encephalopathy risks. Peritoneal dialysis (PD) has emerged as a promising alternative, but its adoption and efficacy are not consistently supported by existing literature, and there lacks guideline consensus.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!